Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.
3D modeling
Abaloparatide
Cortical volumetric BMD
Dual-energy X-ray absorptiometry
Osteoporosis
Teriparatide
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
09
2020
accepted:
17
12
2020
pubmed:
27
1
2021
medline:
19
3
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. In ACTIVE, abaloparatide (ABL) increased bone mineral density (BMD) shown by dual-energy X-ray absorptiometry (DXA) while reducing fracture incidence in postmenopausal osteoporotic women. Changes in DXA BMD with ABL, 80 μg, were significantly greater than with open-label teriparatide (TPTD), 20 μg, at cortical sites including total hip, femoral neck, and 1/3 distal radius. The purpose of this study was to better understand the relative effects of ABL and TPTD on cortical and cancellous compartments in the proximal femur. Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18. Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months. In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD. In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains. These results suggest previously reported differences in areal BMD increases between ABL and TPTD may be due to differential effects on cortical vBMD. Further studies are warranted to investigate how these differences affect therapeutic impact on hip strength in postmenopausal women with osteoporosis.
Identifiants
pubmed: 33496831
doi: 10.1007/s00198-020-05806-1
pii: 10.1007/s00198-020-05806-1
pmc: PMC7929959
doi:
Substances chimiques
Parathyroid Hormone-Related Protein
0
Teriparatide
10T9CSU89I
abaloparatide
AVK0I6HY2U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-583Références
Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149. https://doi.org/10.1210/en.2015-1726
doi: 10.1210/en.2015-1726
pubmed: 26562265
Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [published correction appears in JAMA. 2017 Jan 24;317(4):442]. JAMA 316:722–733. https://doi.org/10.1001/jama.2016.11136
doi: 10.1001/jama.2016.11136
pubmed: 27533157
Tymlos [package insert]. Waltham, MA: Radius Health, Inc; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf . Accessed June 29, 2020.
Watts NB, Hattersley G, Fitzpatrick LA et al (2019) Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis [published correction appears in Osteoporos Int. 2020 May;31(5):1017-1018] [published correction appears in Osteoporos Int. 2020 Jun 12]. Osteoporos Int 30(6):1187–1194. https://doi.org/10.1007/s00198-019-04890-2
doi: 10.1007/s00198-019-04890-2
pubmed: 30899994
pmcid: 6546661
Forteo [package insert]. Indianapolis, IN: Lilly USA, LLC; 2002. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf Accessed June 29, 2020.
Makino A, Takagi H, Takahashi Y et al (2018) Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide. Calcif Tissue Int 103:289–297. https://doi.org/10.1007/s00223-018-0422-4
doi: 10.1007/s00223-018-0422-4
pubmed: 29725706
pmcid: 6105163
Aslan D, Andersen MD, Gede LB et al (2012) Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 72:14–22. https://doi.org/10.3109/00365513.2011.624631
doi: 10.3109/00365513.2011.624631
pubmed: 22085136
Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447–1452. https://doi.org/10.1016/j.bone.2006.09.008
doi: 10.1016/j.bone.2006.09.008
pubmed: 17045858
Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001) Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157–165. https://doi.org/10.1359/jbmr.2001.16.1.157
doi: 10.1359/jbmr.2001.16.1.157
pubmed: 11149480
Sato M, Westmore M, Ma YL et al (2004) Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623–629. https://doi.org/10.1359/JBMR.040112
doi: 10.1359/JBMR.040112
pubmed: 15005850
Hansen S, Hauge EM, Beck Jensen JE, Brixen K (2013) Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res 28:736–745. https://doi.org/10.1002/jbmr.1784
doi: 10.1002/jbmr.1784
pubmed: 23044908
Doyle N, Varela A, Haile S et al (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29:685–697. https://doi.org/10.1007/s00198-017-4323-6
doi: 10.1007/s00198-017-4323-6
pubmed: 29260289
Humbert L, Martelli Y, Fonolla R et al (2017) 3D-DXA: assessing the femoral shape, the trabecular macrostructure and the cortex in 3D from DXA images. IEEE Trans Med Imaging 36:27–39. https://doi.org/10.1109/TMI.2016.2593346
doi: 10.1109/TMI.2016.2593346
pubmed: 27448343
Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, García M, Del Rio L (2018) Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. Osteoporos Int 29:2323-2333. https://doi.org/10.1007/s00198-018-4624-4
Humbert L, Hazrati Marangalou J, Del Río Barquero LM, van Lenthe GH, van Rietbergen B (2016) Technical note: cortical thickness and density estimation from clinical CT using a prior thickness-density relationship. Med Phys 43:1945-1954. https://doi.org/10.1118/1.4944501
Dempster DW, Zhou H, Recker RR et al (2016) Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA Osteoporosis Study. J Clin Endocrinol Metab 101:1353–1363. https://doi.org/10.1210/jc.2015-4181
doi: 10.1210/jc.2015-4181
pubmed: 26859106
pmcid: 4880160
Misof BM, Roschger P, Cosman F et al (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156. https://doi.org/10.1210/jc.2002-021988
doi: 10.1210/jc.2002-021988
pubmed: 12629098
Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644–4649. https://doi.org/10.1210/jc.2004-2489
doi: 10.1210/jc.2004-2489
pubmed: 15914535
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941. https://doi.org/10.1359/jbmr.2003.18.11.1932
doi: 10.1359/jbmr.2003.18.11.1932
pubmed: 14606504
Dempster DW, Zhou H, Recker RR et al (2016) A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial. J Bone Miner Res 31:1429–1439. https://doi.org/10.1002/jbmr.2804
doi: 10.1002/jbmr.2804
pubmed: 26841258
Paggiosi MA, Yang L, Blackwell D et al (2018) Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporos Int 29:1367–1378. https://doi.org/10.1007/s00198-018-4445-5
doi: 10.1007/s00198-018-4445-5
pubmed: 29520607
McClung MR, San Martin J, Miller PD et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass [published correction appears in Arch Intern Med. 2005 Oct 10;165(18):2120]. Arch Intern Med 165:1762–1768. https://doi.org/10.1001/archinte.165.15.1762
doi: 10.1001/archinte.165.15.1762
pubmed: 16087825
Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594. https://doi.org/10.1016/S0140-6736(17)31613-6
doi: 10.1016/S0140-6736(17)31613-6
pubmed: 28755782
Whitmarsh T, Treece GM, Gee AH, Poole KE (2016) The effects on the femoral cortex of a 24 month treatment compared to an 18 month treatment with teriparatide: a multi-trial retrospective analysis. PLoS One 11:e0147722. Published 2016 Feb 9. https://doi.org/10.1371/journal.pone.0147722
doi: 10.1371/journal.pone.0147722
pubmed: 26859142
pmcid: 4747533
Zebaze RM, Ghasem-Zadeh A, Bohte A et al (2010) Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375:1729–1736. https://doi.org/10.1016/S0140-6736(10)60320-0
doi: 10.1016/S0140-6736(10)60320-0
pubmed: 20472174
Bjørnerem Å, Wang X, Bui M et al (2018) Menopause-related appendicular bone loss is mainly cortical and results in increased cortical porosity. J Bone Miner Res 33:598–605. https://doi.org/10.1002/jbmr.3333
doi: 10.1002/jbmr.3333
pubmed: 29218771
Ahmed LA, Shigdel R, Joakimsen RM et al (2015) Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures. Osteoporos Int 26:2137–2146. https://doi.org/10.1007/s00198-015-3118-x
doi: 10.1007/s00198-015-3118-x
pubmed: 25876879
pmcid: 4503860
Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165–170. https://doi.org/10.1016/j.bone.2011.10.002
doi: 10.1016/j.bone.2011.10.002
pubmed: 22015818
Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256. https://doi.org/10.1016/j.bone.2014.07.014
doi: 10.1016/j.bone.2014.07.014
pubmed: 25053463
Mayhew PM, Thomas CD, Clement JG et al (2005) Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet 366:129–135. https://doi.org/10.1016/S0140-6736(05)66870-5
doi: 10.1016/S0140-6736(05)66870-5
pubmed: 16005335
Culler MD, Dong J, Shen Y et al (2001) BIM-44058, a novel analog of PTHrP with enhanced bone building activity, but decreased calcium-mobilization potential [abstract M460]. J Bone Miner Res 16(Suppl 1):324 https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbmr200116s1s1
Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM (2019) Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int 30:667–673. https://doi.org/10.1007/s00198-018-04819-1
doi: 10.1007/s00198-018-04819-1
pubmed: 30635696
pmcid: 6422956